5.615USD+5.25%Mkt Cap: 928.99M USDP/E: —Last update: 2026-06-01
Annexon, Inc., a clinical-stage biopharmaceutical company, discovers and develops medicines for treating inflammatory-related diseases. The company provides Tanruprubart, an investigational full-length monoclonal antibod…
Industry Peers
BiotechnologyIndicators:|
Key Statistics
Company
Market Cap928.99M USD
Enterprise Value688.44M USD
Revenue (TTM)—
Gross Profit—
Net Income (TTM)-206.69M USD
Revenue/Share—
Last Price5.615 USD
Fiscal Year EndDec 2025
MR QuarterMar 2026
Employees93
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)-5.87
PEG—
EV/EBITDA-3.39
EV/Revenue—
P/S—
P/B4.31
EPS (TTM)-1.20
EPS (Forward)-0.92
52W Range
1.85071% of range7.180
52W High7.180 USD
52W Low1.850 USD
Profitability
Gross Margin0.00%
Oper. Margin0.00%
EBITDA Margin0.00%
Profit Margin0.00%
ROE-97.66%
ROA-74.46%
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF-186.36M USD
CapEx (TTM)137.00K USD
FCF Margin—
FCF Yield-11.55%
Net Debt-199.59M USD
Net Debt/EBITDA0.98
Balance Sheet
Debt/Equity0.12
Current Ratio6.35
Quick Ratio6.26
Book Value/Sh1.259 USD
Cash/Share1.373 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 USD
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating1.4 (Strong Buy)
Target (Mean)13.13 USD
Target Range7.000 USD – 27.00 USD
# Analysts8
Ownership
Shares Out.163.84M
Float130.11M
Insiders0.47%
Institutions102.70%
Short Interest
Short Ratio11.5d
Short % Float15.84%
Short % Out.14.82%
Shares Short24.29M
Short (prev mo.)19.68M
Technical
SMA 505.638 (-0.4%)
SMA 2004.516 (+24.3%)
Beta1.22
S&P 52W Chg27.94%
Avg Vol (30d)2.10M
Avg Vol (10d)2.55M
Technical Indicators
RSI (14)45.4
MACD-0.1129
MACD Signal-0.1311
MACD Hist.+0.0182
BB Upper5.930 USD
BB Middle5.430 USD
BB Lower4.930 USD
BB Width18.43%
ATR (14)0.3010 USD
Vol Ratio (20d)0.59x